- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01639638
Recurrent and Nonrecurrent Condyloma Treatment
Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma
Treatment is considered successful if the difference in the response in the reduction of the affected area is above 30% for any of the doses compared to placebo Patients will be randomised to 1 of 3 treatment arms
- Placebo
- CIGB-300 - 5 mg
- CIGB-300 - 15 mg
A two week screening visit will take place to assess patient eligibility, at least 2 to 5 target lesions (area of the lesion between 20 to 80 mm2), should be identified. Patients included in the study will be randomly assigned to one of three study arms. Treatment consists of 3 perilesional applications at the base of the target lesion every 48 hours with a window of ±24hs.
After each application the potential local and systemic adverse events will be identified and monitored.
After the last application is made, weekly clinical evaluations for 3 weeks and then every two weeks, until week 12 will take place. At this time, clinical assessment of efficacy will be carried out that will define the response to treatment.
After this visit, patients will be followed every 3 months until one year after the last treatment has been completed to confirm response and long-term security of the CIGB-300 application.
At screening, at 2 and 8 weeks as well as at 6 and 12 months post-treatment blood studies will be conducted to assess the safety from the systemic point of view.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Buenos Aires
-
Capital Federal, Buenos Aires, Argentina, C1417AZE
- Laboratorio Elea SACIFyA
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Informed consent signed by the patient
- Women with clinical diagnosis of recurrent and non recurrent genital condyloma
- Presence of a condylomatous lesion or area of external confluent condylomatous lesions of not less than 20 or more than 80 mm2
- The number of warts should be between 2 and 20
- External genital warts or in perigenital regions
- Negative pregnancy test
- Age between 18 and 65 years inclusive
Exclusion Criteria:
- Having received surgery treatment, ablative or immunomodulator treatment during the 30 days prior to inclusion
- Presence of genital warts only located in the cervix, vagina, bladder or rectum
- Pregnancy and lactation
- Patients of childbearing age who are not using an adequate contraception method during treatment to prevent pregnancy.
- Inadequately controlled chronic diseases (hypertension, diabetes, chronic kidney failure, heart failure, hyperthyroidism, malignant neoplasms, epilepsy, severe mental depression)
- Patients with previous diagnosis of bleeding disorders and other chronic blood disorders (von Willebrand disease, haemophilia, leukaemia) or use of anticoagulants within 30 days before the study
- Current genital herpes, which requires application of topical antivirals
- Immunosuppressive disease, current intake of immunosuppressive/ immunomodulatory drugs within 30 days before the study.
- Autoimmune Diseases (Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Diabetes)
- Severe allergy history as urticaria, dermatitis or persistent bronchitis and bronchial asthma
- Febrile illness (temperature greater than 38ºC) at the time or within 24 hours prior to administration of the product or suspected acute infectious disease by clinical examination
- Diseases that compromise the patient's consciousness or the ability to give informed consent or to collaborate in the study
- Concomitant skin lesions that prevent the administration of condylomatous lesions at the proposed site
- Participating in another clinical trial
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore placebo: Placebo
|
CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
|
Sperimentale: CIGB-300 - 5 mg
|
CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
|
Sperimentale: CIGB-300 - 15 mg
|
CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Number of patients with complete response of target lesion in each study group
Lasso di tempo: Up to one year
|
Up to one year
|
Number of patients with adverse events during the application of the study drug
Lasso di tempo: Up to one year
|
Up to one year
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Effect of the perilesional application of CIGB300 in the reduction in the number and area of genital warts lesions treated directly
Lasso di tempo: Up to one year
|
Up to one year
|
Locoregional effect of CIGB300 by assessing the area and number of genital warts lesions not directly treated
Lasso di tempo: Up to one year
|
Up to one year
|
Effect of CIGB300 to avoid recurrence of the lesions
Lasso di tempo: Up to one year
|
Up to one year
|
Optimal dose, in comparison with placebo
Lasso di tempo: Up to one year
|
Up to one year
|
Number of patients with adverse events
Lasso di tempo: Up to one year
|
Up to one year
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Malattie della pelle
- Malattie virali
- Infezioni
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Attributi della malattia
- Infezioni da virus del DNA
- Malattie della pelle, infettive
- Verruche
- Infezioni da papillomavirus
- Malattie della pelle, virali
- Infezioni da virus tumorali
- Ricorrenza
- Condilomi Acuminati
Altri numeri di identificazione dello studio
- CONDI 02 AR
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .